Get the Daily Brief
Latest Biotech News
Lilly acquires MeiraGTx eye program – expands genetic‑medicine footprint
Eli Lilly struck an agreement to obtain rights to an experimental ocular gene therapy from MeiraGTx, extending Lilly’s recent string of bets in genetic medicine. The deal gives Lilly rights to a...
Iambic raises more than $100M from ARK and Regeneron to push AI‑bio pipeline
Iambic Therapeutics closed a financing round exceeding $100 million with participation from ARK Invest and Regeneron, the San Diego biotech’s CEO told Endpoints. The cash infusion will accelerate...
Lilly bets up to $1.2B on Sanegene’s LEAD platform for metabolic RNAi
Eli Lilly entered a discovery‑stage collaboration with SanegeneBio that could generate up to $1.2 billion in milestone payments tied to Sanegene’s Ligand and Enhancer Assisted Delivery (LEAD)...
Pfizer clinches Metsera for $10B after bidding war with Novo Nordisk
Pfizer won a competitive acquisition for obesity drug developer Metsera with an up‑to‑$10 billion offer, outbidding Novo Nordisk and resolving a high‑stakes contest that had included litigation....
PACE panel presses for incentives as Ionis touts Tryngolza’s potential
At BIO 2025’s PACE patient advocacy event, industry and patient voices urged stronger incentives and policy protections for Genetically Targeted Technologies (GTTs), citing real‑world benefits...
Pfizer clinches Metsera for $10 billion – Bidding war ends
Pfizer agreed to acquire obesity‑drug developer Metsera in a deal valued at roughly $10 billion, outbidding Novo Nordisk and ending a high‑stakes auction. The offers centered on per‑share cash...
Lilly inks $1.2B pact with Sanegene – RNA delivery deal
Eli Lilly signed a discovery and option agreement with SanegeneBio centered on Sanegene’s LEAD (Ligand and Enhancer Assisted Delivery) platform for tissue‑selective RNAi therapeutics, with...
Merck’s oral PCSK9 pill delivers up to 60% LDL cuts – Phase 3 wins
Merck reported Phase 3 data showing its oral PCSK9 inhibitor produced LDL cholesterol reductions of up to 60% and achieved at least 50% LDL drops in roughly two‑thirds of participants. The trials...
Amgen’s Repatha prevents first heart attacks – VESALIUS‑CV confirms
Amgen released VESALIUS‑CV trial data showing its PCSK9 inhibitor Repatha reduced first‑time cardiovascular events by 25% and cut first heart attacks by 36% in high‑risk patients without prior...
CRISPR therapy slashes LDL and triglycerides in early human study
A CRISPR‑based gene editing therapy from CRISPR Therapeutics reported dramatic reductions in LDL cholesterol and triglycerides in an early human study, according to data presented at a major...
FDA halts Tenaya’s heart gene‑therapy trial over immunosuppression standardization
The FDA placed a clinical hold on Tenaya Therapeutics’ gene therapy study for heart disease while the company standardizes immunosuppression regimens across trial sites. Regulators requested...
Vir posts hepatitis D results, accelerates Phase 3 plans
Vir Biotechnology presented new data for its chronic hepatitis D combo regimen showing sustained viral suppression and supportive safety signals, and said pivotal trials are advancing ahead of...
Multi‑cancer liquid biopsy research suggests earlier detection potential
New research reports that liquid biopsy technologies for multi‑cancer early detection (MCED) could enable screening across multiple cancer types outside current narrow protocols. Investigators...
Prenatal bifidobacterium supplementation alters preterm infant gut microbiome
Researchers reported that prenatal maternal supplementation with bifidobacterium produced measurable changes in the gut microbiome of preterm infants, particularly in pregnancies complicated by...
Recursion names new CEO as losses widen — cash runway extended
AI‑driven drug developer Recursion announced a leadership change, appointing Najat Khan, PhD as CEO while co‑founder Chris Gibson moves to chairman. The company reported mixed Q3 results: widening...
Merck’s oral PCSK9: up to 60% LDL drop in Phase 3
Merck reported Phase 3 data showing its oral PCSK9 inhibitor, enlicitide, reduced LDL cholesterol by up to 60% versus placebo. The trial enrolled about 2,900 patients at high cardiovascular risk...
Amgen’s Repatha: 25% fewer major CV events, 36% fewer first heart attacks
Amgen released VESALIUS‑CV results showing its PCSK9 antibody Repatha reduced major cardiovascular events by 25% in high‑risk patients and cut first heart attacks by 36%, data published in the New...
CRISPR in humans... LDL and triglycerides plunge in early trial
A first‑in‑human CRISPR gene‑editing therapy produced dramatic reductions in LDL cholesterol and triglycerides in an early study of 15 patients, according to STAT reporting from the AHA meeting...
Vir’s hepatitis D combo posts strong suppression; Phase 3 plans accelerate
Vir Biotechnology disclosed new data showing its combination regimen for chronic hepatitis D keeps viral levels low and supports an accelerated Phase 3 program, presented at AASLD. Company...
Pfizer tops Novo Nordisk with $10B Metsera bid – acquisition ends duel
Pfizer won a bidding war for obesity‑drug developer Metsera with an up‑to $10 billion proposal, offering $86.25 per share and edging out Novo Nordisk’s rival offer. The deal resolves an intense...